Emergent BioSolutions Inc EBS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if EBS is a good fit for your portfolio.
News
-
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
-
Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis
-
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility
-
Emergent BioSolutions Shares Drop on S&P Downgrade
-
Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
-
Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024
-
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
-
Emergent BioSolutions stock pulls back, after rallying last week in wake of Biden administration's endorsement of overdose medications
Trading Information
- Previous Close Price
- $1.90
- Day Range
- $1.82–1.99
- 52-Week Range
- $1.42–11.66
- Bid/Ask
- $1.79 / $1.92
- Market Cap
- $97.45 Mil
- Volume/Avg
- 1.1 Mil / 3.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.10
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN® and other commercial products.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 1,600
Comparables
Valuation
|
Metric
|
EBS
|
MRK
|
GSK
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 83.37 | 10.25 |
Price/Book Value | 0.16 | 8.42 | 4.73 |
Price/Sales | 0.10 | 5.30 | 2.16 |
Price/Cash Flow | — | 20.94 | 10.27 |
Price/Earnings
EBS
MRK
GSK
Financial Strength
|
Metric
|
EBS
|
MRK
|
GSK
|
|---|---|---|---|
Quick Ratio | 0.46 | 0.68 | 0.59 |
Current Ratio | 1.04 | 1.25 | 0.88 |
Interest Coverage | −7.32 | 2.33 | 9.30 |
Quick Ratio
EBS
MRK
GSK
Profitability
|
Metric
|
EBS
|
MRK
|
GSK
|
|---|---|---|---|
Return on Assets (Normalized) | −14.17% | 3.59% | 10.54% |
Return on Equity (Normalized) | −34.78% | 9.12% | 50.48% |
Return on Invested Capital (Normalized) | −13.12% | 5.88% | 21.33% |
Return on Assets
EBS
MRK
GSK
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Ynvhglvtw | Lqrzxbp | $70.5 Bil | |
ZTS
| Zoetis Inc Class A | Xmyxplzj | Jcnpq | $69.4 Bil | |
HLN
| Haleon PLC ADR | Mmcxvngr | Bcjq | $36.6 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Yghggkxyg | Kgdw | $14.9 Bil | |
VTRS
| Viatris Inc | Rlxbqhjb | Sdf | $13.2 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Kjtkzmkz | Qhdmb | $12.0 Bil | |
CTLT
| Catalent Inc | Hnjvrytw | Vkjwxf | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Pkvltnnhb | Ddhd | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Dbrydky | Cffhv | $3.7 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Bwdjjbhd | Mlphjf | $3.4 Bil |